Goldman Sachs says this under-the-radar biotech play could more than double in value
Bullish
50.0
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
